Health TrialsbyHealthPanel

Respiratory Support and Treatment for Efficient and Cost-Effective Care

ConditionBronchiolitis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeUp to 2
SponsorChristopher Horvat

About this trial

This project aims to answer the essential questions about the management of acute, pediatric respiratory illness, accelerate recovery from these all-too-common diseases, curb unnecessary costs of care, and demonstrate UPMC Children's Hospital of Pittsburgh's capabilities as the premier, world-class leader in the arena of pediatric learning healthcare systems. REST EEC will focus on the question of whether clinical decision support (CDS) facilitates the standardization of the initiation and weaning of heated high flow nasal cannula (HHFNC) for bronchiolitis.REST EEC will focus on whether the application of CDS improves adherence to a standardized guideline and leads to improved patient-centered outcomes.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

<2 years of age Bronchiolitis WOB Score >2

Disqualifiers

Immunocompromised

Immunosuppressed

Chronic lung disease

Congenital heart disease with baseline cardiorespiratory manifestations

Trial design

Design model

Parallel

Treatments tested in this trial

  • Clinical Decision Support (CDS)

    Other intervention

    Education to front line clinicians and staff on standardized implementation and weaning of HHFNC and standardized assessments of patient work of breathing. HHFNC implementation and weaning strategies will be based on age-specific practices recommended by the American Academy of Pediatrics. Education will be undertaken by dedicated clinical educators.

  • HHFNC Weaning

    Device

    Wean patient off oxygen and flow as oxygenation and work of breathing improves.

Treatment groups

198 Participants
are divided into 2 treatment groups
Group A: HHFNC + Clinical decision SupportExperimental treatment 2 interventions
Group B: HHFNC WeaningActive comparator 2 interventions

Trial outcomes

Primary outcomes

1

HFNC duration

Amount of time patient is on HFNC

Time frame
Timeframe consists of a start time of either randomization or the last documentation of positive pressure ventilation (whichever is later) and the last documentation of HFNC in the electronic flowsheet, up to 30 days

Secondary outcomes

1

Respiratory support free days

Days alive and free of intensive care unit-based respiratory

Time frame
From date the start of respiratory support until the first documented respiratory support free day, up to 30 days
2

Hospital length of stay

Days admitted in hospital

Time frame
From date of admission until discharge or date of death from any cause, whichever came first, assessed up to 90 days.
3

Organ support free days

Days alive and free of ICU-based respiratory or cardiovascular organ support

Time frame
From date of admission until the first day of ICU-based respiratory or cardiovascular organ support or discharge or date of death from any case, whichever came first, assessed up to 30 days
4

Time to oral intake

Time from HHFNC and oral intake

Time frame
From date of ending HHFNC until first documented oral intake, assessed up to 30 days

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Christopher Horvat

Lead sponsor

University of Pittsburgh

Sponsor institution

Beckwith Foundation

Collaborator

Source ClinicalTrials.gov
Apply now